slides · global inventory
Resolution
Beat collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 42,534
Current window 30,121-30,150
Pages 1,418
Rows per page 30
Beat
30,121-30,150 of 42,534
05
The slide uses a list of key benefits to summarize the product's market and clinical position.NeuroSense Therapeutics | Investor Presentation Deck | 34 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · AgitateLoop · Cost Of Inaction1 hit
06
Includes a navigation bar at the bottom indicating the current section is 'PrimeC'.NeuroSense Therapeutics | Investor Presentation Deck | 34 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
07
The slide uses a case study to validate the business/clinical model of combination therapies.NeuroSense Therapeutics | Investor Presentation Deck | 34 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
08
The slide uses a bar chart to compare hazard ratios of multiple compounds against a vehicle control, with statistical significance markers.NeuroSense Therapeutics | Investor Presentation Deck | 34 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
09
Uses a chain-link visual metaphor to represent the combination of two distinct therapeutic strategies.NeuroSense Therapeutics | Investor Presentation Deck | 34 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
10
Includes a line chart showing PK data and a biological diagram illustrating the mechanism of action (blocking MDR-mediated efflux).NeuroSense Therapeutics | Investor Presentation Deck | 34 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
11
The chart highlights the synchronized peak at 5 hours for both active ingredients in the PrimeC formulation compared to reference compounds.NeuroSense Therapeutics | Investor Presentation Deck | 34 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
12
The slide uses a biological process diagram to illustrate how PrimeC modulates microRNA regulation, TDP-43 aggregation, and cellular recycling.NeuroSense Therapeutics | Investor Presentation Deck | 34 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
13
Includes a bar chart of motor performance and visual evidence of motor neuron recovery.NeuroSense Therapeutics | Investor Presentation Deck | 34 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
14
Includes a progress bar at the bottom indicating the current section is 'Phase 2a Results'.NeuroSense Therapeutics | Investor Presentation Deck | 34 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
15
The slide uses a comparative clinical trial analysis against a historical control database (PRO-ACT).NeuroSense Therapeutics | Investor Presentation Deck | 34 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
16
Includes a process diagram showing exosome extraction from blood samples.NeuroSense Therapeutics | Investor Presentation Deck | 34 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
17
Data shows p-values of 0.005 and <0.001 for treated groups, indicating significant biomarker reduction.NeuroSense Therapeutics | Investor Presentation Deck | 34 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
18
The slide uses a process-flow diagram to link trial results to the next phase of development.NeuroSense Therapeutics | Investor Presentation Deck | 34 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
23
NeuroSense Therapeutics | Investor Presentation Deck | 34 slidesNeuroSense Therapeutics | Investor Presentation Deck | 34 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
24
NeuroSense Therapeutics | Investor Presentation Deck | 34 slidesNeuroSense Therapeutics | Investor Presentation Deck | 34 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
25
The slide includes a progress bar at the bottom indicating the current section is 'Summary'.NeuroSense Therapeutics | Investor Presentation Deck | 34 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
26
The slide serves as a media/press coverage page, likely for an appendix.NeuroSense Therapeutics | Investor Presentation Deck | 34 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
27
Includes stock price, market cap, cash position, and analyst coverage.NeuroSense Therapeutics | Investor Presentation Deck | 34 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
28
Includes a team photo and a progress bar at the bottom indicating the current slide is the 'Summary' section.NeuroSense Therapeutics | Investor Presentation Deck | 34 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
29
NeuroSense Therapeutics | Investor Presentation Deck | 34 slidesNeuroSense Therapeutics | Investor Presentation Deck | 34 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
30
This is a highly emotional, narrative-driven slide used to ground the company's mission in a personal story.NeuroSense Therapeutics | Investor Presentation Deck | 34 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
31
The chart shows a negative correlation trend line between TDP-43 change and ALSFRS-R slope.NeuroSense Therapeutics | Investor Presentation Deck | 34 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
32
NeuroSense Therapeutics | Investor Presentation Deck | 34 slidesNeuroSense Therapeutics | Investor Presentation Deck | 34 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
33
The slide serves as a press clipping or media coverage appendix.NeuroSense Therapeutics | Investor Presentation Deck | 34 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
34
Includes a navigation bar at the bottom indicating the current section is 'Phase 2b'.NeuroSense Therapeutics | Investor Presentation Deck | 34 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
17
The slide uses a circular diagram to represent the 'Dry Eye Cycle' and overlays the drug's mechanism of action as an intervention.OKYO Pharma | Results Presentation Deck | 25 slides · OKYO Pharma
Conference presentation Investor relations Beat · Solution1 hit
37
The slide uses a classic sources and uses of cash framework to demonstrate capital allocation strategy.Orbia | Investor Presentation Deck | 62 slides · Orbia
Conference presentation Investor relations Beat · Impact & Next Steps1 hit
38
Orbia | Investor Presentation Deck | 62 slidesOrbia | Investor Presentation Deck | 62 slides · Orbia
Conference presentation Investor relations Beat · Impact & Next Steps1 hit
39
Orbia | Investor Presentation Deck | 62 slidesOrbia | Investor Presentation Deck | 62 slides · Orbia
Conference presentation Investor relations Beat · Impact & Next Steps1 hit